Clinical advantages of new peritoneal dialysis solutions

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 3, 2002, Pages 16-18

  Krediet, Raymond T ^a,b   Van Westrhenen, Roos ^a   Zweers, Machteld M ^a   Struijk, Dirk G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Amino acids; Bicarbonate; Glucose; Glucose degradation products; Icodextrin; Lactate; Peritoneal dialysis solutions; Pyruvate

Indexed keywords

DIALYSIS FLUID; GLUCOSE; LACTIC ACID;

ARTICLE; BIOCOMPATIBILITY; CLINICAL PRACTICE; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; MEDICAL RESEARCH; MEMBRANE DAMAGE; PATIENT CARE; PERITONEAL DIALYSIS; PERITONEUM; PRIORITY JOURNAL;

EID: 0036240685     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_3.16     Document Type: Article

References (29)

1. Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates
2. What happens to patients starting dialysis in the Netherlands
3. An evaluation of an integrated care approach for end-stage renal disease patients
4. Issues affecting the longevity of the continuous peritoneal dialysis therapy
5. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis
6. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis
7. Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat
8. Biocompatibility studies on peritoneal cells
9. P. Acetate versus lactate in peritoneal dialysis solutions
10. Toxicity of osmotic solutes on human mesothelial cells in vitro
11. Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose enriched, lactate buffered dialysis solution
12. Immunohistochemical detection of advanced glycosylation end products in the peritoneum and its possible pathophysiological role in CAPD
13. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vivo model for the study of diabetic microangiopathy
14. Growth factors VEGF and TGF-β1 in peritoneal dialysis
15. Vascular endothelial growth factor in peritoneal dialysis. A longitudinal follow-up
16. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis
17. Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro?
18. Pyruvate anions neutralize peritoneal dialysate toxicity
19. Protective effect of pyruvate upon cultured mesothelial cells exposed to 2 mM hydrogen peroxide
20. Effect of pyruvate on lens myo-inositol transport and polyol formation in diabetic cataract
21. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis
22. Hyperglycemic pseudohypoxia and diabetic complications
23. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor
24. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD
25. Peritoneal transport characteristics with glucose polymer based dialysate
26. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products
27. Cancer antigen 125: A bulk marker for the mesothelial cell mass in stable peritoneal dialysis patients
28. Longitudinal follow-up of CA 125 in peritoneal effluent
29. Continuous dialysis with bicarbonate lactate based peritoneal dialysis solution is associated with an increase in dialysate CA125 and a decrease in hyaluronic acid levels